Key result
Novel Thro-HL score stratifies thrombosis risk in Hodgkin lymphoma up to ~25% in high-risk patients.
Why the study?
Currently, there is no univocal indication to perform thromboprophylaxis in classical Hodgkin lymphoma.
Cohort (n=470)
Yes
The development of the Thro-HL risk model identifies classical Hodgkin lymphoma patients at high risk for thromboembolic events, outperforming the Khorana and ThroLy scores in this specific population.
Answers are grounded in this paper and cite their sources.
Thro-HL may support thrombotic risk stratification in classical Hodgkin lymphoma; leaves open whether prospective validation improves outcomes over existing scores.
Thrombosis Lymphoma (ThroLy) and Khorana scores have been conceived to predict the thrombotic risk in oncohematologic patients. Currently, there is no univocal indication to perform thromboprophylaxis in classical Hodgkin lymphoma (cHL). We performed a retrospective study to validate scores and risk factors in a cohort of consecutive patients with cHL, treated from 2014 to 2022 outside clinical trials. A total of 470 cHL patients without thromboprophylaxis were included, of whom 57 (12%) experienced a thrombotic event (TE) at 3.3 months (range 1–52) from diagnosis. Neither Khorana nor ThroLy score significantly predicted the thrombotic risk. In a multivariate analysis including Throly parameters and other risk factors, an independent prognostic impact on the TE risk was found for bulky disease (3 points), ECOG PS 2–4 (2 points), presence of peripherally implanted central venous catheter (2 points), mediastinal involvement (1 point), which were combined in a new risk model (Thro‐HL). Low‐risk (score 0–1; 39%, n = 183), intermediate‐risk (score 2–3; 46%, n = 214), and high‐risk (score > 3; 15%, n = 72) patients had a significantly different TE rate, of 2.7%, 16%, and 25% (P < 0.001), respectively. Three‐year‐thrombotic event‐free survival was 97% (CI 95–100) for low‐risk and 76% (CI 66–86) for high‐risk patients (P < 0.0001, Harrel's C ‐index = 0.70). Thro‐HL could be a promising tool to be validated in larger series.
No takes yet. Share an insight, caveat, or question.
Assanto et al. (2025) conducted a cohort in Classical Hodgkin lymphoma (cHL) (n=470). Thro-HL high risk score vs. Thro-HL low risk score was evaluated on Thrombotic event (TE) rate (p=<0.001). A new disease-specific Thro-HL score stratified classical Hodgkin lymphoma patients into low, intermediate, and high risk groups for thrombotic events.
Synapse has enriched 10 related papers. Consider them for comparative context: